8-K: Co-Diagnostics Reports Q3 2025 Results, Strategic Moves

Co-Diagnostics, Inc. announced its third quarter 2025 financial results, reporting a significant revenue decrease but improved net loss, alongside strategic initiatives including a new KSA joint venture and an AI business unit.

Summary

• Revenue for the third quarter ended September 30, 2025, was $0.1 million, a decrease from $0.6 million in Q3 2024, primarily due to reduced grant revenue.
• Operating expenses decreased by 32.6% year-over-year to approximately $7.1 million in Q3 2025.
• The company reported an operating loss of $7.0 million, an improvement from $10.2 million in Q3 2024.
• Net loss for Q3 2025 was $5.9 million, or $0.16 per fully diluted share, compared to a net loss of $9.7 million, or $0.32 per fully diluted share, in Q3 2024.
• Adjusted EBITDA loss for Q3 2025 was $6.3 million.
• Cash, cash equivalents, and marketable securities stood at $11.4 million as of September 30, 2025.
• During Q3 2025, the company closed a Registered Direct Offering (RDO) with gross proceeds of approximately $3.8 million before expenses.
• Subsequent to quarter end, another RDO was closed, generating gross proceeds of approximately $7.0 million before expenses.
• A definitive agreement was signed with Arabian Eagle Manufacturing to establish CoMira Diagnostics, a joint venture for research, development, manufacturing, distribution, and commercialization of Co-Dx technologies in KSA and 18 MENA nations.
• A new artificial intelligence (AI) business unit was formed, led by Chief Technology & AI Officer Christopher Thurston, to integrate AI applications into the Co-Dx Primer Ai platform.
• A proprietary sample preparation instrument designed to streamline workflow for point-of-care (PoC) Co-Dx PCR Mycobacterium Tuberculosis (MTB) Test was developed.
• Maxim Group LLC was engaged to pursue a strategic transaction, potentially a SPAC, for CoSara Diagnostics, the company's joint venture in India.
• In-silico analysis of Co-Primers-based PCR tests for chikungunya virus (CHIKV) showed high homology against over 1,200 CHIKV sequences and confirmed reactivity against recent strains.

Sentiment

Score: 4

Explanation: While the company has made significant strategic moves (JVs, AI unit, potential SPAC), the core financial results for Q3 2025 show a substantial decline in revenue and continued losses, indicating ongoing operational challenges despite efforts to raise capital and expand.

Positives

• Net loss significantly improved to $5.9 million ($0.16 per diluted share) in Q3 2025 from $9.7 million ($0.32 per diluted share) in Q3 2024.
• Operating expenses decreased by 32.6% year-over-year, demonstrating cost management efforts.
• Successfully completed two Registered Direct Offerings, raising approximately $3.8 million (Q3) and $7.0 million (post-Q3) in gross proceeds, enhancing liquidity.
• Established CoMira Diagnostics, a joint venture in Saudi Arabia and 18 MENA nations, significantly expanding international market reach.
• Formed a new AI business unit and developed a proprietary sample preparation instrument, indicating continued technological innovation and product pipeline development.
• Engaged Maxim Group LLC to explore strategic options for the India joint venture, CoSara Diagnostics, which could unlock shareholder value.
• Confirmed high homology and reactivity of chikungunya virus (CHIKV) primers through in-silico analysis, validating test design.

Negatives

• Revenue decreased significantly to $0.1 million in Q3 2025 from $0.6 million in Q3 2024, primarily due to a reduction in grant revenue.
• The company reported an operating loss of $7.0 million and a net loss of $5.9 million, indicating ongoing unprofitability.
• Adjusted EBITDA loss was $6.3 million, reflecting continued operational losses.
• Total assets decreased from $63.9 million at December 31, 2024, to $44.7 million at September 30, 2025.
• Marketable investment securities decreased from $26.8 million at December 31, 2024, to $0 at September 30, 2025, suggesting conversion to cash or other assets.

Risks

• Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances, and actual results may differ materially from those anticipated.
• There is no assurance that any of the anticipated results from strategic initiatives will occur on a timely basis or at all due to certain risks and uncertainties, as discussed in the Annual Report on Form 10-K.
• The Co-Dx PCR platform (including PCR Home, PCR Pro, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

Future Outlook

Co-Diagnostics is entering a strategically important period, aiming for sustainable growth, expanded global reach, and long-term value creation through initiatives like the CoMira Diagnostics joint venture, potential strategic transaction for CoSara, the new AI business unit, and upcoming clinical evaluations for its upper-respiratory multiplex test.

Management Comments

• "We are entering one of the most active and strategically important periods in our Companys history." Dwight Egan, Co-Diagnostics Chief Executive Officer.
• "CoMira Diagnostics, our new joint venture in the Kingdom of Saudi Arabia, establishes a strong commercial presence in the KSA and 18 additional MENA markets, expanding our international footprint and supporting the localization of advanced molecular diagnostics in one of the worlds fastest-growing healthcare regions." Dwight Egan, Co-Diagnostics Chief Executive Officer.
• "Additionally, our recently-announced engagement of Maxim to pursue a strategic transaction, including a SPAC transaction with our India joint venture, CoSara, if completed, would represent a significant step toward unlocking value from our India joint venture for our shareholders." Dwight Egan, Co-Diagnostics Chief Executive Officer.
• "In parallel, we have launched a dedicated AI business unit to unify our proprietary applications under the Co-Dx Primer Ai platform and are preparing to initiate clinical evaluations for our upper-respiratory multiplex test supported by a grant from the NIHs RADx Tech program." Dwight Egan, Co-Diagnostics Chief Executive Officer.
• "Together, these initiatives reflect the execution of a cohesive strategy built on financial strength, technological innovation, and scientific leadership that is intended to position Co-Diagnostics for potential sustainable growth, expanded global reach, and long-term value creation." Dwight Egan, Co-Diagnostics Chief Executive Officer.

Industry Context

The company's focus on expanding into the MENA region through a joint venture aligns with global trends of increasing healthcare investment and demand for advanced diagnostics in emerging markets. The formation of an AI business unit and development of point-of-care PCR tests reflect the broader industry shift towards integrating artificial intelligence for enhanced diagnostic capabilities and decentralized testing solutions, particularly for infectious diseases like tuberculosis and respiratory illnesses.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for value unlocking from CoSara JV, dilution from RDOs, and long-term growth from strategic initiatives.
• Employees: Formation of new AI business unit led by Christopher Thurston may indicate new roles or focus areas.
• Customers: Development of new diagnostic tests (CHIKV, MTB PoC, upper-respiratory multiplex) and expansion into MENA markets could offer new diagnostic solutions.
• Creditors: Financial performance and capital raises impact the company's ability to meet obligations.

Next Steps

• Initiate clinical evaluations for the upper-respiratory multiplex test, supported by a grant from the NIH's RADx Tech program.
• Pursue a strategic transaction, potentially a SPAC, for CoSara Diagnostics (India joint venture) with Maxim Group LLC.
• Continue to integrate existing and planned AI applications into the Co-Dx Primer Ai platform.
• Further develop, manufacture, assemble, distribute, and commercialize Co-Dx technologies and intellectual property in KSA and 18 MENA nations through the CoMira Diagnostics JV.
• Seek regulatory review for the Co-Dx PCR platform (including PCR Home, PCR Pro, mobile app, and associated tests) to make it available for sale.

Key Dates

Recommendation

While the company's Q3 2025 financial results show a significant revenue decline and continued losses, the strategic initiatives, including the new CoMira Diagnostics JV, the formation of an AI business unit, and the engagement of Maxim Group for CoSara, indicate potential for future growth and value creation. The recent capital raises provide liquidity for these initiatives. Investors should hold to observe the execution and impact of these strategic moves, particularly the progress of the JVs and the AI platform, before making further investment decisions.

Keywords

Molecular Diagnostics, PCR Tests, Chikungunya Virus, AI Business Unit, Co-Dx Primer Ai, Point-of-Care, Mycobacterium Tuberculosis, Joint Venture, Saudi Arabia, MENA, India, SPAC, Registered Direct Offering, Financial Results, Q3 2025, CODX, Biotechnology, Healthcare Technology